- Home
- RIGL vs ZTR Comparison
RIGL vs ZTR Comparison
Compare RIGL & ZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- ZTR
- Stock Information
- Founded
- RIGL 1996
- ZTR 1988
- Country
- RIGL United States
- ZTR Australia
- Employees
- RIGL N/A
- ZTR N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- ZTR Investment Managers
- Sector
- RIGL Health Care
- ZTR Finance
- Exchange
- RIGL Nasdaq
- ZTR Nasdaq
- Market Cap
- RIGL 335.5M
- ZTR 349.4M
- IPO Year
- RIGL 2000
- ZTR N/A
- Fundamental
- Price
- RIGL $38.85
- ZTR $6.37
- Analyst Decision
- RIGL Buy
- ZTR
- Analyst Count
- RIGL 5
- ZTR 0
- Target Price
- RIGL $38.20
- ZTR N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- ZTR 219.4K
- Earning Date
- RIGL 08-05-2025
- ZTR 01-01-0001
- Dividend Yield
- RIGL N/A
- ZTR 12.09%
- EPS Growth
- RIGL N/A
- ZTR N/A
- EPS
- RIGL 5.43
- ZTR N/A
- Revenue
- RIGL $267,921,000.00
- ZTR N/A
- Revenue This Year
- RIGL $59.93
- ZTR N/A
- Revenue Next Year
- RIGL N/A
- ZTR N/A
- P/E Ratio
- RIGL $7.15
- ZTR N/A
- Revenue Growth
- RIGL 105.62
- ZTR N/A
- 52 Week Low
- RIGL $12.66
- ZTR $4.50
- 52 Week High
- RIGL $43.72
- ZTR $6.60
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- ZTR 64.07
- Support Level
- RIGL $39.00
- ZTR $6.27
- Resistance Level
- RIGL $42.08
- ZTR $6.35
- Average True Range (ATR)
- RIGL 2.32
- ZTR 0.04
- MACD
- RIGL -0.37
- ZTR 0.01
- Stochastic Oscillator
- RIGL 53.26
- ZTR 85.06
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.